ANI Pharmaceuticals

ANIP

Market cap $2.01B

ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

ANI (ANIP) could produce exceptional returns because of its solid growth attributes.

Here is how ANI Pharmaceuticals (ANIP) and Celldex Therapeutics (CLDX) have performed compared to their sector so far this year.

ANI (ANIP) could produce exceptional returns because of its solid growth attributes.

The volatile biotech industry has done reasonably well so far in 2025 amid the ongoing tariff saga. Most pharma/biotech bigwigs are now investing heavily in manufacturing plants/operations in the United States as the Trump administration threatened of levying heavy tariffs on pharmaceutical imports (upto 250%) in a bid to boost domestic production.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:50 PM EDT Company Participants Nikhil Lalwani - President, CEO & Director Conference Call Participants Daniel Cohen - Morgan Stanley Presentation Daniel Cohen Okay. Good Afternoon, everybody.

ANI (ANIP) could produce exceptional returns because of its solid growth attributes.

ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Does ANI Pharmaceuticals (ANIP) have what it takes to be a top stock pick for momentum investors? Let's find out.